Highlights Cosmo Pharmaceuticals N.V.

Equities

COPN

NL0011832936

Delayed Swiss Exchange Other stock markets 07:55:47 2024-04-29 am EDT			5-day change	1st Jan Change
71.7 ^CHF	+0.14%		-2.32%	+40.86%

Apr. 26	Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024	CI
Apr. 25	Cosmo Pharmaceuticals Names New CEO, Chairman	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cosmo Pharmaceuticals N.V. Proposes Dividend Payment for 2024	Mar. 20	CI
Cosmo Pharmaceuticals N.V. Provides Earnings Guidance for the Year 2024 and Revenue Guidance for 2025	Mar. 20	CI
Cosmo Pharmaceuticals' FY23 Profit, Revenue Drops	Mar. 20	MT
Cosmo Pharmaceuticals N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Medtronic Expands Partnership With Cosmo Pharmaceuticals Unit	Dec. 11	MT
Cosmo Pharmaceuticals, Medtronic to Boost AI Focus in Expanded Partnership	Dec. 11	MT
Cosmo Pharmaceuticals Redeems EUR175 Million of Bonds due 2023	Dec. 06	MT
Global markets live: Nvidia, Chevron, FedEx, Roche, PepsiCo...	23-10-10
Cosmo Pharmaceuticals Files Marketing Authorization Application in Europe for Topical Acne Treatment	23-10-10	MT
Cosmo Pharmaceuticals Licenses Acne Treatment Winlevi to Hikma in Middle East, North Africa	23-10-02	MT
Cosmo Pharmaceuticals Signs Distribution, Licensing Deals with Glenmark for Acne Cream in Europe, South Africa	23-09-27	MT
Cosmo Pharmaceuticals N.V. and Glenmark Specialty S.A. Announce the Signing of Distribution and License Agreements for Winlevi® in Europe and South Africa	23-09-27	CI
Cosmo Pharmaceuticals Signs License Deal With Adalvo for Rifamycin	23-09-04	MT
Cosmo Pharmaceuticals Cancels Dr. Falk Pharma's EU License for Travelers' Diarrhea Drug	23-09-04	MT
Cosmo Pharmaceuticals N.V. Reiterates Earnings Guidance for the Year 2023	23-07-26	CI
Cosmo Pharmaceuticals N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-26	CI
Cosmo Pharmaceuticals Posts Lower H1 Post-tax Profit; Revenue Rises	23-07-26	MT
Cosmo Pharmaceuticals N.V. Announces the Beginning of the Phase III Trials in Men for the Treatment of Androgenetic Alopecia	23-06-29	CI
Cosmo Pharmaceuticals Wins Japanese Nod For Ulcerative Colitis Drug	23-06-28	MT
Cosmo Pharmaceuticals Licenses Topical Acne Medication to Hyundai Pharmaceuticals in South Korea	23-06-22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cosmo Pharmaceuticals N.V.

Equities

COPN

NL0011832936

Highlights

Filters